Updated:
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a public biotech developing oral amphotericin B for serious fungal infections via its LNC platform.
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company publicly listed on the NYSE American under ticker MTNB. Founded in 2013, the firm is led by CEO Jerome D. Jabbour. The company's wealth originates from public equity markets, not a private family fortune. The firm's strategy centers on its proprietary lipid nanocrystal (LNC) platform, designed to enable oral delivery of potent but toxic drugs. The lead asset, MAT2203 (oral amphotericin B), is in Phase 2 trials for cryptococcal meningitis and Phase 1 for invasive aspergillosis (per ClinicalTrials.gov, 2024). Matinas also has preclinical candidates in antifungal and antiviral areas. The firm does not manage third-party capital; its operations are funded by equity offerings and grants. As of May 2025, Matinas employed roughly 15–20 people, per public filings. The company has no disclosed additional offices beyond its headquarters in Bedminster, New Jersey. In December 2024, the firm reported positive safety and tolerability data from its Phase 2a study of MAT2203 (per Matinas press release, December 2024). The structural differentiator is Matinas' LNC platform, which aims to solve the longstanding challenge of oral delivery for amphotericin B, a gold-standard antifungal whose IV-only formulation limits use. This technology could enable outpatient treatment, reducing hospitalization costs and improving access in resource-limited settings. Matinas' business model as a development-stage public biotech, rather than an asset manager, places it outside typical family office or fund structures.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Matinas BioPharma Holdings, Inc.?
Investment decisions are made by the board of directors and senior management, led by CEO Jerome D. Jabbour. The company does not operate as an investment manager; its capital allocation is centered on clinical development. Public filings disclose executive compensation and stock ownership, but not a separate investment committee.
How does Matinas BioPharma source proprietary deal flow?
Matinas generates its pipeline internally via its LNC platform, not through deal sourcing or external acquisitions. The firm has partnered with BARDA (Biomedical Advanced Research and Development Authority) for MAT2203 development. No disclosed licensing or joint venture activity beyond government collaborations.
Is Matinas BioPharma structured as a single family office or does it operate more like a venture firm?
Matinas is a publicly traded biopharmaceutical company (NYSE: MTNB), not a family office or venture firm. Its corporate structure includes a board of directors, executive team, and shareholders. The firm's primary purpose is drug development, not capital management.
Does Matinas BioPharma participate in fund commitments or only direct deals?
Matinas does not participate in fund commitments or direct deal investing. As a development-stage biotech, its activities are restricted to clinical trials, regulatory interactions, and operations. The firm's funding comes from equity raises, grants, and collaborations.
What investment stages does Matinas BioPharma typically target?
Matinas does not target investment stages; it is a drug developer focused on clinical-stage candidates. Its lead asset is in Phase 2 trials, with earlier work in preclinical stages. The firm's value proposition hinges on regulatory milestones, not investment returns.
Which sectors does Matinas BioPharma explicitly avoid?
Matinas focuses exclusively on serious infectious diseases, particularly fungal and viral infections. The firm avoids oncology, rare diseases, and other therapeutic areas where its LNC platform has not demonstrated applicability. Publicly disclosed pipelines are limited to anti-infectives.
How is Matinas BioPharma related to parent or related vehicles?
Matinas BioPharma is a standalone public company with no parent or related family office. Its largest shareholders are institutional investors disclosed in SEC filings. No known connections to private family offices or venture funds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: